Recipient, donor, graft, intraoperative, and early postoperative characteristics of the entire study population and according to recipient etiology of liver disease (HCV negative versus HCV positive).
All patients (n= 204)
HCV positive (n= 82)
HCV negative (n= 122)
P value HCV positive vs HCV negative
RECIPIENT
Age (years)
56.00 (49.14-61.00)
57.00 (49.00-61.00)
55.50 (49.75-61.25)
0.510
Gender (female)
49 (24.0)
22 (26.8)
27 (22.1)
0.441
MELD score
15.20 (12.26-18.65)
14.73 (12.46-18.85)
15.72 (11.78-18.15)
0.549
BMI (kg/m2)
25.46 (23.28-28.47)
26.23 (23.91-28.64)
25.06 (23.04-28.34)
0.184
HCC (yes vs no)
78 (38.2)
32 (39.0)
46 (37.7)
0.849
DONOR
Age (years)
50.50 (33.25-64.00)
48.00 (31.00-65.00)
51.00(34.00-64.00)
0.703
Gender (female)
84 (41.2)
32 (39.0)
52 (42.6)
0.609
BMI (kg/m2)
24.83 (23.44-27.06)
24.69 (23.44-26.15)
25.39 (23.61-27.34)
0.131
Cause of death (non trauma vs trauma)
132 (65.7)
50 (61)
82 (68.9)
0.244
ALT (IU/L)
33.00 (18.00-58.50)
33.00 (18.00-59.00)
32.50 (17.75-58.50)
0.562
AST (IU/L)
37.50 (25.00-70.50)
45.50 (24.00-83.00)
36.00 (25.00-58.50)
0.174
Sodium (mEq/L)
149.00 (142.25-157.00)
150.00 (142.00-157.00)
149.00 (144.00-157.00)
0.804
Hemoglobin (gr/dL)
10.50 (9.30-12.20)
10.40 (9.00-11.90)
10.70 (9.50-12.30)
0.440
PaO2 (mmHg)
150.50 (102.93-202.08)
148.90 (111.50-217.50)
151.00 (98.00-198.00)
0.776
Anti-HBc status (pos vs neg)
18 (8.8)
3 (3.7)
15 (12.3)
0.043
Norepinephrine (yes vs no)
98 (49.0)
33 (40.7)
65 (54.6)
0.054
ICU stay (days)
3.00 (2.00-7.00)
3.00 (2.00-6.00)
4.00 (2.00-8.00)
0.113
GRAFT
Sd-MaS categorical, n (%):
0%
118 (57.8)
49 (59.8)
69 (56.6)
0.613
1-15%
52 (25.5)
18 (22.0)
34 (27.9)
>15%
34 (16.7)
15 (18.3)
19 (15.6)
Sd-MaS, continuous variable (% of hepatocytes)
0.00 (0.00-5.00)
0.00 (0.00-10.00)
0.00 (0.00-5.00)
0.969
Ld-MaS categorical, n (%):
0% (reference)
88 (43.1)
39 (47.6)
49 (40.2)
0.530
1-15%
92 (45.1)
35 (42.7)
57 (46.7)
>15%
24 (11.8)
8 (9.8)
16 (13.1)
Ld-MaS, continuous variable (% of hepatocytes)
2.00 (0.00-9.00)
1.00 (0.00-5.00)
2.00 (0.00-10.00)
0.245
Cold ischemia time (minutes)
361.00 (280.75-415.00)
357.50 (270.00-421.25)
362.50 (298.25-410.00)
0.606
Warm ischemia time (minutes)
60.00 (47.50-77.75)
60.00 (45.75-87.75)
60.00 (48.50-75.00)
0.316
IRI score, categorical§ (severe vs mild/moderate)
40 (29.9)
19 (34.5)
21 (26.6)
0.322
IPGF (yes vs no)
37 (18.3)
15 (18.5)
22 (18.2)
0.952
EAD (yes vs no)
112 (54.9)
48 (58.5)
64 (52.5)
0.392
Transplant year
6.00 (3.00-8.75)
5.00 (3.00-7.00)
6.00 (3.00-9.00)
0.105
MELD, model for end-stage liver disease score; HCC, hepatocellular carcinoma; PaO2, partial pressure of oxygen in arterial blood; ICU, intensive care unit; Sd-MaS, small droplet macrovesicular steatosis; Ld-MaS, large droplet macrovesicular steatosis; IRI, histological ischemia/reperfusion injury; IPGF, initial poor graft function; EAD, early allograft dysfunction. Continuous variable is expressed as median (25th-75th percentile); the differences between groups were evaluated by Mann-Whitney U test or T test according to the variable normality. Categorical variables were expressed as count (percentages) and compared by the chi-square or Fisher’s exact test. §Available in only 55 and 79 recipients with HCV positive and negative liver disease, respectively.
